Goodbye, Chris. You will be missed.
From her former lab as can be read in the comments:
“A memorial service for Christina in Sacramento is in the works and I will pass along that information to the BMCDB GG when I receive it.
– Matt Wood”
Learn how to be a better mentor and teacher! Next week will be the first Entering Mentoring seminar for the Winter quarter. This seminar is open to graduate students, postdocs, and even professors that want to enhance their abilities as a mentor. This Winter we will hold 6 weekly 1-hour seminars covering topics common to all mentoring relationships.
Here are just a few benefits of participating in the Mentoring Seminar:
1. Enhance your mentoring abilities through awareness and learn tools for effective mentoring
2. Gain perspective on all mentoring relationships, including your own student/PI relationship
3. Put on your CV that you took a HHMI Entering Mentoring Seminar
4. Free coffee and bagels on Wednesday mornings!
Time: Wednesday mornings from 9:00am to 10:00am
Dates: February 2nd through March 7th (6 weeks long)
Place: 148 Briggs Hall
Our tentative weekly schedule will focus on the following topics:
1. Establishing a good mentoring relationship, and elements of a good research project
2. Learning to communicate effectively and adaptively
3. Setting goals and expectations, and developing trust
4. Identifying and resolving challenges in mentoring
5. Evaluating your progress as a mentor
6. Developing a mentoring philosophy and drawing parallels in mentoring
To sign up, subscribe to the EnteringMentoring listserve at: https://lists.ucdavis.edu/sympa/info/enteringmentoring or email Brandon Zipp (email@example.com) or Kristi Bezold (firstname.lastname@example.org) for more information.
Feel free to email with any questions that you might have. I look forward to seeing you next Wednesday!
From the Roswell Park Cancer Institute
Dendritic cell vaccine, manufactured in unique RPCI facility, trains body’s defenses to remember, destroy cancer cell.
The Center for Immunotherapy at Roswell Park Cancer Institute (RPCI) has launched a phase I clinical research study of a dendritic cell vaccine designed to both eradicate cancer cells and prevent disease relapse. Developed at RPCI, the NY-ESO-1 dendritic cell vaccine will be manufactured in the Institute’s new Therapeutic Cell Production Facility using a unique FDA-approved process — making RPCI the first research facility in the U.S. to use a custom-made barrier isolator for vaccine cell production, and the first in the world to use this system in an approved, government-regulated study.
Dendritic cells are the gatekeepers of the human immune system, defending against invaders like bacteria, viruses and cancer. The vaccine to be produced at RPCI will be the first to incorporate a particular form of NY-ESO-1, antiDEC205-NY-ESO-1. “Armed with this specialized protein, the treated cells are then given back to the patient as a vaccine designed to recruit an army of killer immune cells that seek out and destroy cancer,” explains Kunle Odunsi, MD, PhD, Director of RPCI’s Center for Immunotherapy (CFI) and the study’s Principal Investigator.
The new study is also unique in that it’s the first to test a dendritic vaccine given in combination with rapamycin, a compound used to prevent rejection of solid-organ transplant. The study just launched will capitalize on a striking recent scientific discovery by Protul Shrikant, PhD, of the Department of Immunology at RPCI, who found that in low doses, rapamycin confers a previously unknown benefit — it prevents the immune system from using up its cancer-killing T-cells in one quick burst. “We have shown for the first time that rapamycin has the capacity to produce immune cells that have memory attributes,” explains Dr. Odunsi, who is also Chair of RPCI’s Department of Gynecologic Oncology. “The immune cells are trained to live longer and to always remember that cancer cells are bad and should be attacked and killed.”
The ability to stretch out the attack for a long-term, durable response suggests that the vaccine may be effective in preventing disease recurrence. The new NY-ESO-1 dendritic cell vaccine is expected to show great promise in patients with bladder, brain, breast, esophageal, gastrointestinal, hepatocellular, kidney, lung, melanoma, ovarian, prostate, sarcoma and uterine tumors.
The NY-ESO-1 vaccine, tailor-made for each patient, will be produced in RPCI’s Therapeutic Cell Production Facility (TCPF) under the direction of Yeong “Christopher” Choi, PhD, who notes: “We believe that our facility’s custom-made barrier isolator, the unit in which the vaccines are manufactured, is the first of its kind.” The barrier isolator — an Xvivo System processing chamber designed to RPCI’s specifications by BioSpherix, Ltd., Lacona, NY — maintains strict control of the unit’s temperature and atmospheric gases, critical for optimal production of dendritic cell vaccines.
“Those conditions, and the sterile vaccine-manufacturing environment, are rigidly maintained throughout the entire process,” says Dr. Choi. “The Xvivo — which at about 70 square feet is basically a clean room in a box — acts as a physical barrier that protects the cell-therapy product from outside contaminants, resulting in a safer, more predictable manufacturing process.”
Read the complete article here.
A recent press release from UC San Diego by Susan Brown:
Neal Devaraj watches as undergraduate student Weilong Li works on a next step in their quest to create an entirely artificial cell.
Chemists have taken an important step in making artificial life forms from scratch. Using a novel chemical reaction, they have created self-assembling cell membranes, the structural envelopes that contain and support the reactions required for life.
Neal Devaraj, assistant professor of chemistry at the University of California, San Diego, and Itay Budin, a graduate student at Harvard University, report their success in the Journal of the American Chemical Society.
“One of our long term, very ambitious goals is to try to make an artificial cell, a synthetic living unit from the bottom up – to make a living organism from non-living molecules that have never been through or touched a living organism,” Devaraj said. “Presumably this occurred at some point in the past. Otherwise life wouldn’t exist.”
By assembling an essential component of earthly life with no biological precursors, they hope to illuminate life’s origins.
“We don’t understand this really fundamental step in our existence, which is how non-living matter went to living matter,” Devaraj said. “So this is a really ripe area to try to understand what knowledge we lack about how that transition might have occurred. That could teach us a lot – even the basic chemical, biological principles that are necessary for life.”
Molecules that make up cell membranes have heads that mix easily with water and tails that repel it. In water, they form a double layer with heads out and tails in, a barrier that sequesters the contents of the cell.
Devaraj and Budin created similar molecules with a novel reaction that joins two chains of lipids. Nature uses complex enzymes that are themselves embedded in membranes to accomplish this, making it hard to understand how the very first membranes came to be.
“In our system, we use a sort of primitive catalyst, a very simple metal ion,” Devaraj said. “The reaction itself is completely artificial. There’s no biological equivalent of this chemical reaction. This is how you could have a de novo formation of membranes.”
Read the complete article here.